Top Biotech Companies in Atlanta, GA (58)
Loyal is a clinical-stage veterinary biotechnology company dedicated to extending the healthy lifespan of dogs. The company develops pharmaceutical therapies and longevity drugs that target the underlying biological processes of aging to delay the onset of age-associated diseases and preserve quality of life for senior dogs, pioneering a new category of preventative veterinary prescription drugs.
OUR PURPOSE Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. OUR CREDENTIALS Kuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange since 2016. With additional operations in the Netherlands and the USA, we continue to grow our global team. To deliver the ideal bone graft, you need the highest quality and quantity of...
Atlanta Center for Reproductive Medicine (ACRM) is a state-of-the-art fertility center specializing in the diagnosis and treatment of infertility and reproductive endocrinology disorders. Founded in 1998, it is one of the largest centers in the metropolitan area, providing care in Advanced Reproductive Technologies (ART), including in-vitro fertilization (IVF), pre-genetic diagnosis (PGD), and egg recipiency, with a mission to help patients...
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with...
Roche's Top Stability & Growth Strengths
Strong Market Position & Advantage: Roche is the global leader in in‑vitro diagnostics and remains a top‑tier biopharma with a significant oncology footprint. The dual Pharmaceuticals–Diagnostics model is a strategic differentiator at scale.
Strong Revenue Growth: Group sales rose 7% at constant exchange rates in 2025 and 6% at CER in Q1 2026, with both divisions contributing. Guidance for 2026 indicates continued mid–single‑digit CER growth.
Profitability: Profitability improved in 2025 alongside sales, with higher IFRS net income and core EPS growth. Management pointed to capacity to keep investing while rewarding shareholders.
Impiricus is the future of HCP-industry engagement. We build valuable tools, and curate trusted information for our network of providers. We partner with Pharma to identify the most impactful innovation to highlight. With the worlds first AI Concierge, we are supporting 1 mio patients get on therapy by 2025. Our physicians never have to fight an insurance company again. Want to...
A trusted partner at nearly three million customer locations, Ecolab (ECL) is the global leader in water, hygiene and infection prevention solutions and services. With annual sales of $12 billion and more than 44,000 associates, Ecolab delivers comprehensive solutions, data-driven insights and personalized service to advance food safety, maintain clean and safe environments, optimize water and energy use, and improve...
Ecolab's Top Stability & Growth Strengths
Profitability: Record sales, earnings per share, and operating margins in 2024 and 2025 indicate sustained margin improvement. Feedback suggests continued expansion is expected in 2026 supported by pricing discipline, productivity, and higher‑margin services.
Strong Market Position & Advantage: Ecolab is consistently characterized as a global leader across water, hygiene, and infection prevention with broad industry reach and high customer retention. Feedback suggests external accolades and large-scale operations reinforce a durable competitive moat.
Innovation-Driven Growth: Expansion into high-growth areas like hyperscale data centers, microelectronics, and life sciences is supported by acquisitions and digital services. Feedback suggests AI-enabled analytics, performance-based contracts, and a growing backlog are fueling future growth.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers...
Bio-Techne's Top Stability & Growth Strengths
Profitability: Adjusted EPS and operating margins expanded despite muted top-line trends, including a 31.1% adjusted operating margin in the most recent quarter. Cost and productivity actions supported margin improvement even as sales were flat year over year.
Strong Market Position & Advantage: Leadership in niches such as immunoassays and high-quality proteins (R&D Systems), RNA-ISH (RNAscope), and automated protein analysis (ProteinSimple) underpins competitive strength. In-house manufacturing control over most reagents reinforces quality and consistency across core categories.
Future-Ready Strategy: Focus on cell therapy, proteomic instrumentation, spatial biology, and precision diagnostics has expanded as a share of revenue and aligns with high-growth workflows. Acquisitions and strategic stakes (e.g., Lunaphore, Wilson Wolf/ScaleReady) position the portfolio for emerging demand.
At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and...
Elekta's Top Stability & Growth Strengths
Strong Market Position & Advantage: Elekta is a top-tier radiotherapy vendor with category leadership in cranial stereotactic radiosurgery and a notable presence in high-field MR-guided therapy, reinforcing durable competitive standing. Recognition for oncology information systems further supports its positioning in cancer centers.
Innovation-Driven Growth: Recent launches such as Elekta Evo and the Elekta ONE software suite, alongside continued advancement of Unity MR‑Linac workflows, indicate a pipeline that is aiding orders and improving mix. These innovations underpin adaptive and image‑guided therapy strategies across the portfolio.
Resilient & Sustainable Growth: Book‑to‑bill ratios above 1.0 and low single‑digit constant‑currency sales growth point to steady underlying expansion. Improving adjusted margins in recent quarters suggest operational gains despite macro headwinds.
Vanigent is a fast-growing Contract Sales Organization (CSO) based in Atlanta, serving the biotechnology and pharmaceutical industries. With a leadership team averaging 25 years of life sciences experience, we deliver strategic and commercial solutions across multiple therapeutic areas while upholding the highest standards of innovation, compliance, and integrity. Our approach combines decades of field expertise with technology-driven solutions that help clients...
CorDx a multi-national biotech organization focused on pushing the limits of innovation and supply in global health. With over 2,100 employees across the world, serving millions of users in over 100 countries, CorDx delivers rapid testing and point-of-care medical device solutions used in the detection of infectious disease such as COVID-19, pregnancy, drugs of abuse, biomarkers, and more. CorDx is...
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
10,000 people, one global focus - enhancing the health and well-being of pets, people, and livestock. We are passionate about what we do at IDEXX – and why wouldn’t we be? When you’re working to raise the standard of care for pets, make drinking water safe for billions and keep our livestock population around the globe healthy and free of...
IDEXX's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show double‑digit top‑line increases in 2025 and early 2026, with Q1 and Q2 2026 up 14% and 10% reported, respectively, and full‑year 2026 revenue guidance raised. Growth is broad‑based across Companion Animal Group diagnostics, Water, and LPD.
Profitability: Margin expansion is attributed to recurring diagnostics volume, pricing, and productivity, translating into higher EPS and operating leverage. Guidance and quarterly updates highlight continued earnings growth if these drivers are maintained.
Strong Market Position & Advantage: The company is widely regarded as the category leader in companion‑animal diagnostics, reinforced by an integrated ecosystem of instruments, consumables, labs, imaging, and software. Independent analyses consistently place it at or near the top across key diagnostics segments, supporting durable advantage.
PathGroup is an industry-leading provider of comprehensive anatomic, clinical, and molecular pathology services in the United States. It serves as the pathology provider for over 250 hospitals and thousands of physician groups and surgery centers. Physician-led and physician-centered, PathGroup is designed to work seamlessly with medical practices, providing direct consultation and high-quality laboratory testing and results.
Xylem |ˈzīləm| 1) The tissue in plants that brings water upward from the roots; 2) a leading global water technology company. Xylem, a leading global water technology company dedicated to solving the world’s most challenging water issues, is the leading global provider of efficient, innovative and sustainable water technologies improving the way water is used, managed, conserved and re-used. Our international team is...
IHRC, Inc. is a science-centered consulting and professional services firm that delivers bioinformatics, data science & analytics, epidemiology, laboratory science, and management consulting to public health and government clients. Founded in 2007 and headquartered in Atlanta, IHRC supports CDC and other agencies with data-driven health solutions, government contracting, and applied research to advance disease detection, prevention, and public-health decision making.
Lincare is a leading supplier of respiratory-therapy products and services for patients in the home. You can learn more about our extensive suite of products and services by visiting our website. Everywhere we operate, Lincare is working to be a partner in patient care by providing high-quality services and supplies, promoting patient education, and building strong relationships with patients, physicians,...
Vero biotech is an emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions. At Vero Biotech, our mission is to improve the lives of patients by leading the development of innovative technologies for inhaled NO delivery in the acute care hospital...
At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial...
Varian's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry analyses frequently describe external‑beam radiotherapy as a Varian–Elekta near‑duopoly, with Varian often cited at or near the top. Feedback suggests a large installed base, leading software stack, and a broad global service footprint reinforce this position.
Strong Revenue Growth: Company and trade updates state the Varian segment has posted year‑over‑year revenue growth across multiple recent periods within Siemens Healthineers, alongside positive order momentum and a growing backlog. Feedback suggests recent quarterly trends point to continued demand for systems, software, and services.
Strategic Partnerships: Integration with Siemens Healthineers provides access to imaging, diagnostics, and digital platforms, enabling end‑to‑end oncology workflows and cross‑selling advantages. Feedback suggests this parent‑level backing strengthens global reach and execution in tenders.
Amniox Medical provides amniotic membrane and umbilical cord regenerative tissue therapies.
